The ICBcircSig score was validated based on the weighted expression of circTMTC3 and circFAM117B from melanoma in patients receiving anti-PD-1 or combined anti-CTLA4 and anti-PD-1 therapy. The gene discussed is PDCD1; the disease is melanoma.